Fulcrum Therapeutics, Inc. (FULC) Financial Statements
Fulcrum Therapeutics, Inc. (FULC) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$85.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$66.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FULCFulcrum Therapeutics, Inc.Follow FULC — free
—
Price chart with a free account
- Market cap
- 280.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.8 | 19.2 | 6.3 | 2.8 | 80.0 | 0.0 | — | |
| Gross profit | — | — | 5.9 | — | 77.9 | — | — | |
| Research & development | 59.0 | 69.7 | 76.8 | 71.8 | 63.4 | 56.1 | 56.2 | |
| Operating income | -71.6 | -81.1 | -112.6 | -110.7 | -21.9 | -84.8 | -96.0 | |
| Pre-tax income | -70.8 | -80.8 | -109.9 | -97.3 | -9.7 | -74.9 | -85.0 | |
| Income tax | — | — | — | — | — | 0.0 | — | |
| Net income | -70.8 | -80.8 | -109.9 | -97.3 | -9.7 | -74.9 | -85.0 | |
| Diluted EPS ($) | -2.79 | -2.29 | -2.44 | -1.59 | -0.16 | -1.18 | -1.11 | |
| Diluted shares (mn) | — | 35.4 | 45.0 | 61.3 | 62.0 | 63.4 | — |
USD millions · SEC XBRL
Fulcrum Therapeutics, Inc. — questions
- What is Fulcrum Therapeutics, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Fulcrum Therapeutics, Inc.'s net income?
- -$85.0M over the twelve months to 2026-06-30.
- What is Fulcrum Therapeutics, Inc.'s free cash flow?
- -$66.1M over the twelve months to 2026-06-30.
- What are Fulcrum Therapeutics, Inc.'s diluted earnings per share?
- $-1.11 over the twelve months to 2026-06-30.
Every figure on this page comes from Fulcrum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.